Migraine headache is a pervasive but poorly understood primary pain disorder. Sumatriptan and the 'triptan' class of serotonin receptor subtype-selective drugs have wellestablished efficacy in treating the pain of migraine. Although sumatriptan was originally selected to target vasoactive properties thought to be fundamental to the etiology of migraine, other studies point to an action of triptans at several levels of the nervous system. To this day, however, it is not clear whether the antimigraine activity of the triptans involves an action only in the periphery or in the CNS as well. Because sumatriptan is hydrophilic, it penetrates the blood-brain barrier poorly, suggesting a peripheral site of action. On the other hand, it has been proposed that the barrier is compromised in migraineurs, so a CNS site of action has not been ruled out. Finally, the basis for the apparent selectivity of triptans in the treatment of migraine pain but not other kinds of somatic pain is still not understood. Determining that mechanism of triptan action will likely provide important new insights into the unique and essential features of migraine.
Peripheral mechanisms
Graham and Wolff (1938) first proposed that the pain of migraine results from abnormal cranial vascular distention. They were influenced by (1) the association between migraine relieving properties of ergotamine tartrate infusion and arterial vasoconstriction and (2) the finding that compression of the common carotid artery or superficial temporal artery reduces pain in many migraine attacks. Although the relationship between vascular changes and migraine was still uncertain, the vasoactive, serotonergic properties of ergotamine on isolated artery and vein preparations led to the development of sumatriptan, a serotonergic agonist with selective activity on 5-HT 1B , 5-HT 1D , and 5-HT 1F receptors. The vasoconstrictive properties of triptans are mediated by an action on 5-HT 1B in arterial smooth muscle. On the other hand, although sumatriptan-mediated vasoconstriction can dose-dependently increase blood flow velocity in middle cerebral vessels, because these vascular changes are not temporally related to the resolution of the migraine attack (Limmroth et al., 1996) , it is still unclear whether triptan activation of vascular 5-HT 1B receptors is necessary for the treatment of migraine.
The triptans are also thought to inhibit the abnormal activation of peripheral nociceptors. In an experimental model of migraine, called sterile neurogenic inflammation, an abnormal activation of nociceptors in the dura mater triggers vascular changes, including plasma protein extravasation (PPE) (Moskowitz and Cutrer, 1993) . The triptans reduce PPE, presumably by inhibiting the activation of nociceptors and preventing the peripheral release of vasoactive peptides, including substance P and calcitonin gene related peptide (CGRP). Venous CGRP itself provides another useful measure of peripheral neuronal activation. In animal models and in humans, CGRP is elevated in the external jugular vein after stimulation of the trigeminal ganglion as well as during migraine attacks. Consistent with a peripheral action for triptans, treatment with sumatriptan 
